SlideShare a Scribd company logo

applied strategic biosimilars success

applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.

1 of 15
Download to read offline
applied strategic
10 years experience in biosimilars: launch
to the future. What matters most?
Presentation by Dr Richard Littlewood
9 March 2016
8th Biosimilars Congregation
applied strategic 1
Analytics
What we all know? Definition of similarity concept for
biologic medicines defined a new market for biosimilars
applied strategic 2
Preclinical
PK/PD
Clinical
Trials
Process
development
Source: McCamish 2011, CMHP/437/04
Biological
Characterization
Physiochemical
Characterization
“A company may choose to
develop a new biological medicinal
product claimed to be “similar” to a
reference medicinal product”
CHMP/437/04
What do we expect? Rapid growth to $35B global market
for biosimilars, predicted by observers
applied strategic 3
Biosimilars global sales
[2013-2020, $B]
60%
CAGR
Biosimilars
Biologics
175
285
2013 2020
Source: Merck Serono 2014, Blackstone & Joseph 2013, EGA 2015, Evaluate Group 2014
When did it start? Radical regulatory affairs innovation by
EMEA, 2004 and key guidance launched biosimilars
applied strategic Source: applied strategic analysis EMA
Legal progress
Regulatory progress
2001 2002 2003 2004 2005 2006
Directive 2003/63/EC
“Annex I” biosimiars
recognition
Directive
2004/27/EC
published
Directive
2004/27/EC
in law
First
biosimilar
approved
Product
guidelines
hGh, insulin,
EPO, G-CSF
Comparability
guidelines
Quality, non-
clinical,
clinical
guidelines
Where did it start? In Europe work started pre-2000;
alternative biologics versions were marketed in LATAM also
applied strategic 5
Europe
1998: Start development of
Binocrit® (epoetin alfa)
Mexico
1999: launch of Bioyetin
(epoetin alfa)
Source: applied strategic analysis
What is the impact? Early product launches in Europe
highlight commercial and patient access success
applied strategic 6
• Launch of biosimilar Epoetin
alfa in Europe
• 5 year healthcare cumulative
savings to Germany, €0.6B
• Typically 35% cost reduction
• 255,000 patient-years
exposure
Biosimilar Epoetin Alfa
Launch 2007
Commercial & patient access
success
Source: applied strategic analysis
What is the impact? A relatively small set of biosimilar
products are currently marketed
applied strategic 7
Omnitrope
Silapo
EpoHexal
Binocrit
Abseamed
Tevalgrastim
Ratiograstim
Biograstim
Retracrit
Nivestim
Remsima
Ovaleap
Inflectra
Grastofil
Bemfola
Accofil
Abasglar
Benepali
Zarzio
FilgrastimHexal
20162006 2011
Source: GaBI, Biosimilars approved in Europe 2016
European product approvals
What is the impact? Few companies own a majority of the
assets: market looks an oligopoly…
applied strategic 8
Omnitrope
Silapo
EpoHexal
Binocrit
Abseamed
Tevagrastim
Ratiograstim
Biograstim
Retracrit
Nivestim
Remsima
Ovaleap
Inflectra
Grastofil
Bemfola
Accofil
Abasglar
Benepali
Zarzio
FilgrastimHexal
20162006 2011
Source: GaBI, Biosimilars approved in Europe 2016
European product approvals
Assets owned by companies with
portfolio of biosimiars
What is the future? Patent expiry, freedom to operate for
many biologics defines a $B expansion of opportunity
Monoclonal antibodies approved/ under review in EU/ US
[Patent expiry]
applied strategic 9
Oncology
Non-
oncology
17
32
<2020 >2020
Source: applied strategic analysis
• 49 monoclonal antibody
products have potential for
biosimilar launch
• Launch of biosimilar
versions of these products
represents a step change
in opportunity size
Potential value $20-30B
Expiry of
patent, year
What is the future? New biosimilar products – based on
antibodies – imply increasing manufacturing complexity
applied strategic 10
Trade Name (INN) Originator Approval date
Tysabri® (Natalizumab) Biogen Idec 2004
Lucentis® (Ranibizumab) Roche/ Novartis 2006
Cimzia® (Certolizumab) UCB 2009
Stelara® (Ustekinumab) Johnson & Johnson 2009
Eylea® (Aflibercept) Bayer/ Regeneron 2011
Zaltrap® (Aflibercept) Sanofi/ Regeneron 2012
Prolia®/Xgeva® (Denosumab) Amgen 2011
Benlysta® (Belimumab) GlaxoSmithKline 2011
Soliris® (Eculizumab) Alexion 2007, 2011
Source: applied strategic analysis
• Future products with potential to be biosimilars are based on antibodies
• Greater manufacturing complexity, defining a special capability need
What is the future? Success with biosimilars is driving
increasing simplicity in evidence needed for approval
applied strategic 11
“a confirmatory clinical trial may
not be necessary”
EMA 2014
“waiving clinical trials may be
accomplishable for biosimilar
rhG-CSF”
EMA 2015
“pre-licensing safety study,
immunogenicity assessment
waived?
EMA 2015
“PK PD results may make a
comparative efficacy study
unnecessary”
FDA 2015
Source: applied strategic analysis
What is the future? A broad range of competitors now are
present: partners are a major part of the business
applied strategic 12
Merck Sorono, Merck
Pfizer, Daiichi-Sankyo
Boehringer Ingelheim,
biogen idec
Baxter, Lilly, Amgen
Sandoz, Teva
Hospira, Mylan
STADA, Dr. Reddy’s,
actavis. Cipla, Gideon
Richter
Fujifilm
Samsung
GE Healthcare
Celltrion
Innovative
companies
Generics
manufacturers Others
Biocon
Lonza
Formycon
Patheon
Intas
IBA Bioton
Zydus
Broughton
Zydus
Wockhardt
CMC
Rentschler
Key partners: supporting development, contract development, manufacturers
Competitors: Commercializing biosimilar products
Source: applied strategic analysis
What drives success? First commercial phase. Success
factors: protein characterization, regulatory affairs
applied strategic 13
Development Clinical Regulatory Launch Commercial
Cell line to product
development; protein
characterization;
comparability
Agency relationships,
strategic leadership;
pathway interpretation
Tender management,
pricing strategy.
Customer awareness
Customer awareness,
defending against
restrictions;
Policy management
Success Factors for Biosimilar Competition: First Commercial Phase
(2006-2016)
What drives success? Next 10 years Success factors:
commercial power, speed to market
applied strategic 14
Development Clinical Regulatory Launch Commercial
Complex protein
manufacture
R&D partnerships
Capability to delivery
clinical studies rapidly
Marketing & Sales
power
Race to market
Success Factors for Biosimilar Competition: Second Commercial Phase
(2017-2027)
Speaker profile
Dr. Richard Littlewood
• Richard is the founder of the strategy firm
applied strategic
• is a physician with clinical practice experience
and a management consultant who has worked
for 15 years addressing strategic and operational
issues in health, pharma
• He is a UK GMC registered physician, has an
MA from Trinity College, Cambridge and is a
graduate of the Sloan Masters management
program at London Business School.
• Richard pioneered on biosimilars strategy and
has extensive experience in many developed
and emerging markets.
15
[appliedstrategic founder]
Dr. Richard Littlewood
• Adviser to global pharmaceutical companies
involved in biosimilar development in Europe,
USA and emerging markets since 2006
[Conflicts]

Recommended

applied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsapplied strategic 10 years vision for biosimilars
applied strategic 10 years vision for biosimilarsRichard Littlewood
 
BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends    BIOSIMILARS - Regulation and Market Trends
BIOSIMILARS - Regulation and Market Trends Joseph Pategou
 
BioProcess International Keynote
BioProcess International KeynoteBioProcess International Keynote
BioProcess International Keynotevandenboom
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Ajaz Hussain
 
Merck presentation.
Merck presentation.Merck presentation.
Merck presentation.Bakryk
 
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
 
Antibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisAntibody drug conjugate market opportunity analysis
Antibody drug conjugate market opportunity analysisRajesh Sarma
 

More Related Content

What's hot

Merck & co., inc. barclays final 3-10-2015
Merck & co., inc.   barclays final 3-10-2015Merck & co., inc.   barclays final 3-10-2015
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
 
Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Joseph Pategou
 
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
 
Market elements of the biopharmaceutical market and single-use technologies
Market elements of the biopharmaceutical market and single-use technologiesMarket elements of the biopharmaceutical market and single-use technologies
Market elements of the biopharmaceutical market and single-use technologiesBenoit Massé
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Rollrahulranjan138
 
Complex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and ChallengesComplex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and ChallengesSanjay Chaturvedi
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsSandoz
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketJoanne Toran McHugh
 
Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pipelinepharma
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to  MedicinesMerck: Global Health and Access to  Medicines
Merck: Global Health and Access to MedicinesTony Sebastian
 
SBM-Investor-Presentation-Apr-2022.pdf
SBM-Investor-Presentation-Apr-2022.pdfSBM-Investor-Presentation-Apr-2022.pdf
SBM-Investor-Presentation-Apr-2022.pdfMomentumPR
 
Reducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentReducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentAjaz Hussain
 
OBI Pharma presentation at JP Morgan Healthcare Conference 2018
OBI Pharma presentation at JP Morgan Healthcare Conference 2018OBI Pharma presentation at JP Morgan Healthcare Conference 2018
OBI Pharma presentation at JP Morgan Healthcare Conference 2018Gus Adapon, ELS
 
171123 Presentation BioMed Elements
171123 Presentation BioMed Elements171123 Presentation BioMed Elements
171123 Presentation BioMed ElementsSMBBV
 
Market Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch ActMarket Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch ActMichael Swit
 
How Patent and Regulatory Exclusivity can Protect Your Medical Device Business
How Patent and Regulatory Exclusivity can Protect Your Medical Device BusinessHow Patent and Regulatory Exclusivity can Protect Your Medical Device Business
How Patent and Regulatory Exclusivity can Protect Your Medical Device BusinessMichael Weickert, Ph.D
 
Biosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic DrugsBiosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic Drugsindexcalculation
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsCovance
 

What's hot (19)

Merck & co., inc. barclays final 3-10-2015
Merck & co., inc.   barclays final 3-10-2015Merck & co., inc.   barclays final 3-10-2015
Merck & co., inc. barclays final 3-10-2015
 
Biosimilars: Regulation Issues
Biosimilars: Regulation Issues Biosimilars: Regulation Issues
Biosimilars: Regulation Issues
 
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market
 
Biosimilar Dug Development
Biosimilar Dug DevelopmentBiosimilar Dug Development
Biosimilar Dug Development
 
Market elements of the biopharmaceutical market and single-use technologies
Market elements of the biopharmaceutical market and single-use technologiesMarket elements of the biopharmaceutical market and single-use technologies
Market elements of the biopharmaceutical market and single-use technologies
 
Generics, Industry on the Roll
Generics, Industry on the RollGenerics, Industry on the Roll
Generics, Industry on the Roll
 
Complex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and ChallengesComplex Generics Overview - Outlooks and Challenges
Complex Generics Overview - Outlooks and Challenges
 
Expanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilarsExpanding Sandoz leadership in biosimilars
Expanding Sandoz leadership in biosimilars
 
Navigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar MarketNavigant: The Birth of An Orphan Biosimilar Market
Navigant: The Birth of An Orphan Biosimilar Market
 
Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to  MedicinesMerck: Global Health and Access to  Medicines
Merck: Global Health and Access to Medicines
 
SBM-Investor-Presentation-Apr-2022.pdf
SBM-Investor-Presentation-Apr-2022.pdfSBM-Investor-Presentation-Apr-2022.pdf
SBM-Investor-Presentation-Apr-2022.pdf
 
Reducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar developmentReducing technical and regulatory uncertinty in biosimilar development
Reducing technical and regulatory uncertinty in biosimilar development
 
OBI Pharma presentation at JP Morgan Healthcare Conference 2018
OBI Pharma presentation at JP Morgan Healthcare Conference 2018OBI Pharma presentation at JP Morgan Healthcare Conference 2018
OBI Pharma presentation at JP Morgan Healthcare Conference 2018
 
171123 Presentation BioMed Elements
171123 Presentation BioMed Elements171123 Presentation BioMed Elements
171123 Presentation BioMed Elements
 
Market Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch ActMarket Exclusivity Under the Waxman-Hatch Act
Market Exclusivity Under the Waxman-Hatch Act
 
How Patent and Regulatory Exclusivity can Protect Your Medical Device Business
How Patent and Regulatory Exclusivity can Protect Your Medical Device BusinessHow Patent and Regulatory Exclusivity can Protect Your Medical Device Business
How Patent and Regulatory Exclusivity can Protect Your Medical Device Business
 
Biosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic DrugsBiosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic Drugs
 
Pharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for BiosimilarsPharmacovigilance Risk Management for Biosimilars
Pharmacovigilance Risk Management for Biosimilars
 

Viewers also liked

A comparative study about toxicity of CdSe quantum dots on reproductive syste...
A comparative study about toxicity of CdSe quantum dots on reproductive syste...A comparative study about toxicity of CdSe quantum dots on reproductive syste...
A comparative study about toxicity of CdSe quantum dots on reproductive syste...Nanomedicine Journal (NMJ)
 
Big data analytics to step change in pathology services
Big data analytics to step change in pathology servicesBig data analytics to step change in pathology services
Big data analytics to step change in pathology servicesRichard Littlewood
 
applied margin presentation leiden 2016 v2.0
applied margin presentation leiden 2016 v2.0applied margin presentation leiden 2016 v2.0
applied margin presentation leiden 2016 v2.0Richard Littlewood
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars successRichard Littlewood
 
Applied aatod presentation highlights
Applied aatod presentation highlightsApplied aatod presentation highlights
Applied aatod presentation highlightsRichard Littlewood
 
Housing for people with opioid use disorder
Housing for people with opioid use disorderHousing for people with opioid use disorder
Housing for people with opioid use disorderRichard Littlewood
 

Viewers also liked (6)

A comparative study about toxicity of CdSe quantum dots on reproductive syste...
A comparative study about toxicity of CdSe quantum dots on reproductive syste...A comparative study about toxicity of CdSe quantum dots on reproductive syste...
A comparative study about toxicity of CdSe quantum dots on reproductive syste...
 
Big data analytics to step change in pathology services
Big data analytics to step change in pathology servicesBig data analytics to step change in pathology services
Big data analytics to step change in pathology services
 
applied margin presentation leiden 2016 v2.0
applied margin presentation leiden 2016 v2.0applied margin presentation leiden 2016 v2.0
applied margin presentation leiden 2016 v2.0
 
applied strategic biosimilars success
applied strategic biosimilars successapplied strategic biosimilars success
applied strategic biosimilars success
 
Applied aatod presentation highlights
Applied aatod presentation highlightsApplied aatod presentation highlights
Applied aatod presentation highlights
 
Housing for people with opioid use disorder
Housing for people with opioid use disorderHousing for people with opioid use disorder
Housing for people with opioid use disorder
 

Similar to applied strategic biosimilars success

applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...Richard Littlewood
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014Fen Castro
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 Fen Castro
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014Virtue Insight
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)chetanpatel73
 
5th biosimilars congregation 2014
5th biosimilars congregation 20145th biosimilars congregation 2014
5th biosimilars congregation 2014Nisha Virtue
 
7th Annual Biosimilars (2010)
7th Annual Biosimilars (2010)7th Annual Biosimilars (2010)
7th Annual Biosimilars (2010)jaayboy69
 
Biosimilars-emerging market in india
Biosimilars-emerging market in indiaBiosimilars-emerging market in india
Biosimilars-emerging market in indiaPRUTHVIRAJ. U
 
EBR_October-15_pp.30-34 (Molekule)
EBR_October-15_pp.30-34 (Molekule)EBR_October-15_pp.30-34 (Molekule)
EBR_October-15_pp.30-34 (Molekule)David Alderman
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Debashish Kar
 
Follow on Biologics Market
Follow on Biologics MarketFollow on Biologics Market
Follow on Biologics MarketSanjay Modi
 
Biocon Investors Presentation July 2013
Biocon Investors Presentation July 2013Biocon Investors Presentation July 2013
Biocon Investors Presentation July 2013Biocon
 
Pharma Focus Asia Issue 21
Pharma Focus Asia Issue 21Pharma Focus Asia Issue 21
Pharma Focus Asia Issue 21yahyasultan
 
Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Allied Market Research
 
Download Global biosimilars market regulations &amp; pipeline insight
Download Global biosimilars market regulations &amp; pipeline insightDownload Global biosimilars market regulations &amp; pipeline insight
Download Global biosimilars market regulations &amp; pipeline insightKuicK Research
 

Similar to applied strategic biosimilars success (20)

applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...
applied INSIGHTS: 10 year perspective on biosimilars, prediction for success ...
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014 5th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
5th Biosimilars Congregation 2014
5th Biosimilars Congregation 20145th Biosimilars Congregation 2014
5th Biosimilars Congregation 2014
 
Biosimilars global congress 2014 europe copy 3 (6)
Biosimilars global congress 2014 europe  copy 3 (6)Biosimilars global congress 2014 europe  copy 3 (6)
Biosimilars global congress 2014 europe copy 3 (6)
 
5th biosimilars congregation 2014
5th biosimilars congregation 20145th biosimilars congregation 2014
5th biosimilars congregation 2014
 
7th Annual Biosimilars (2010)
7th Annual Biosimilars (2010)7th Annual Biosimilars (2010)
7th Annual Biosimilars (2010)
 
Korea entry strategy (biocon)
Korea entry strategy (biocon)Korea entry strategy (biocon)
Korea entry strategy (biocon)
 
Korea entry strategy (biocon) Hypothetical
Korea entry strategy (biocon) HypotheticalKorea entry strategy (biocon) Hypothetical
Korea entry strategy (biocon) Hypothetical
 
Biosimilars-emerging market in india
Biosimilars-emerging market in indiaBiosimilars-emerging market in india
Biosimilars-emerging market in india
 
8th biosimilars congregation 2016
8th biosimilars congregation 20168th biosimilars congregation 2016
8th biosimilars congregation 2016
 
8th biosimilars congregation 2016
8th biosimilars congregation 20168th biosimilars congregation 2016
8th biosimilars congregation 2016
 
EBR_October-15_pp.30-34 (Molekule)
EBR_October-15_pp.30-34 (Molekule)EBR_October-15_pp.30-34 (Molekule)
EBR_October-15_pp.30-34 (Molekule)
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
 
Follow on Biologics Market
Follow on Biologics MarketFollow on Biologics Market
Follow on Biologics Market
 
Biocon Investors Presentation July 2013
Biocon Investors Presentation July 2013Biocon Investors Presentation July 2013
Biocon Investors Presentation July 2013
 
Pharma Focus Asia Issue 21
Pharma Focus Asia Issue 21Pharma Focus Asia Issue 21
Pharma Focus Asia Issue 21
 
Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market Biosimilars follow on-biologics - market
Biosimilars follow on-biologics - market
 
Download Global biosimilars market regulations &amp; pipeline insight
Download Global biosimilars market regulations &amp; pipeline insightDownload Global biosimilars market regulations &amp; pipeline insight
Download Global biosimilars market regulations &amp; pipeline insight
 

Recently uploaded

Dentists in Juhu, Mumbai, Dental Concepts
Dentists in Juhu, Mumbai, Dental ConceptsDentists in Juhu, Mumbai, Dental Concepts
Dentists in Juhu, Mumbai, Dental Conceptsriachasharma1
 
CHAPTER ONE Makerere University Uganda.pdf
CHAPTER ONE Makerere University Uganda.pdfCHAPTER ONE Makerere University Uganda.pdf
CHAPTER ONE Makerere University Uganda.pdfYIKIISAAC
 
Roar Wellness Drug Addiciton Program.pdf
Roar Wellness Drug Addiciton Program.pdfRoar Wellness Drug Addiciton Program.pdf
Roar Wellness Drug Addiciton Program.pdfroarwellnessrehab
 
ram forum 3.pptx Disease X the upcoming pandemic
ram forum 3.pptx Disease X the upcoming pandemicram forum 3.pptx Disease X the upcoming pandemic
ram forum 3.pptx Disease X the upcoming pandemicRam Prasad
 
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMS
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMSFAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMS
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMSRommel Luis III Israel
 
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdf
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdfDr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdf
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdfد حاتم البيطار
 
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky Mahajan
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky MahajanThe Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky Mahajan
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky MahajanSilky Mahajan
 
INTESTINAL OBSTRUCTION.pptx...smart study..
INTESTINAL OBSTRUCTION.pptx...smart study..INTESTINAL OBSTRUCTION.pptx...smart study..
INTESTINAL OBSTRUCTION.pptx...smart study..Beena Vaza
 
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptx
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptxThe Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptx
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptxDr. David Greene Arizona
 
Integrated Health Information Platform (IHIP)
Integrated Health Information Platform (IHIP)Integrated Health Information Platform (IHIP)
Integrated Health Information Platform (IHIP)ssuser57d97d
 
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSING
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSINGINTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSING
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSINGSheenaSaju1
 
School Health Services in Community Health Nursing
School Health Services in Community Health NursingSchool Health Services in Community Health Nursing
School Health Services in Community Health NursingVeereshDemashetti
 
Everything You Need To Know About Bone Mineral Density Test
Everything You Need To Know About Bone Mineral Density TestEverything You Need To Know About Bone Mineral Density Test
Everything You Need To Know About Bone Mineral Density TestPixel Diagnostics
 
quangnguyen22624444444444444444444 .pptx
quangnguyen22624444444444444444444 .pptxquangnguyen22624444444444444444444 .pptx
quangnguyen22624444444444444444444 .pptxTyraRideaux
 
tayloranderson12222222222222222222222222222222.pptx
tayloranderson12222222222222222222222222222222.pptxtayloranderson12222222222222222222222222222222.pptx
tayloranderson12222222222222222222222222222222.pptxTyraRideaux
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertensionKhyber medical university
 
Artificial intelligence in Dermatology.pptx
Artificial intelligence in Dermatology.pptxArtificial intelligence in Dermatology.pptx
Artificial intelligence in Dermatology.pptxSiddharthDash13
 
tayloranderson44444444444444444444444444444444.pptx
tayloranderson44444444444444444444444444444444.pptxtayloranderson44444444444444444444444444444444.pptx
tayloranderson44444444444444444444444444444444.pptxTyraRideaux
 
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision MedicineAdoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision MedicineClinosolIndia
 
Strategies and Options For Making India Zero Waste Water-26-2-24.pptx
Strategies and Options For Making India Zero Waste Water-26-2-24.pptxStrategies and Options For Making India Zero Waste Water-26-2-24.pptx
Strategies and Options For Making India Zero Waste Water-26-2-24.pptxJIT KUMAR GUPTA
 

Recently uploaded (20)

Dentists in Juhu, Mumbai, Dental Concepts
Dentists in Juhu, Mumbai, Dental ConceptsDentists in Juhu, Mumbai, Dental Concepts
Dentists in Juhu, Mumbai, Dental Concepts
 
CHAPTER ONE Makerere University Uganda.pdf
CHAPTER ONE Makerere University Uganda.pdfCHAPTER ONE Makerere University Uganda.pdf
CHAPTER ONE Makerere University Uganda.pdf
 
Roar Wellness Drug Addiciton Program.pdf
Roar Wellness Drug Addiciton Program.pdfRoar Wellness Drug Addiciton Program.pdf
Roar Wellness Drug Addiciton Program.pdf
 
ram forum 3.pptx Disease X the upcoming pandemic
ram forum 3.pptx Disease X the upcoming pandemicram forum 3.pptx Disease X the upcoming pandemic
ram forum 3.pptx Disease X the upcoming pandemic
 
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMS
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMSFAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMS
FAMILY HEALTH NURSING- TYPOLOGY OF FAMILY HEALTH PROBLEMS
 
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdf
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdfDr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdf
Dr. Ahmed Samhanد حاتم البيطاررر اكاديمية زويل .pdf
 
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky Mahajan
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky MahajanThe Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky Mahajan
The Ultimate Guide to a Type 2 Diabetes-Friendly Diet by Silky Mahajan
 
INTESTINAL OBSTRUCTION.pptx...smart study..
INTESTINAL OBSTRUCTION.pptx...smart study..INTESTINAL OBSTRUCTION.pptx...smart study..
INTESTINAL OBSTRUCTION.pptx...smart study..
 
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptx
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptxThe Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptx
The Science of Healing Dr. David Greene on Stem Cells for Burn Injuries (1).pptx
 
Integrated Health Information Platform (IHIP)
Integrated Health Information Platform (IHIP)Integrated Health Information Platform (IHIP)
Integrated Health Information Platform (IHIP)
 
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSING
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSINGINTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSING
INTRODUCTION TO HEALTH AND ILLNESS for 1st SEM BSc NURSING
 
School Health Services in Community Health Nursing
School Health Services in Community Health NursingSchool Health Services in Community Health Nursing
School Health Services in Community Health Nursing
 
Everything You Need To Know About Bone Mineral Density Test
Everything You Need To Know About Bone Mineral Density TestEverything You Need To Know About Bone Mineral Density Test
Everything You Need To Know About Bone Mineral Density Test
 
quangnguyen22624444444444444444444 .pptx
quangnguyen22624444444444444444444 .pptxquangnguyen22624444444444444444444 .pptx
quangnguyen22624444444444444444444 .pptx
 
tayloranderson12222222222222222222222222222222.pptx
tayloranderson12222222222222222222222222222222.pptxtayloranderson12222222222222222222222222222222.pptx
tayloranderson12222222222222222222222222222222.pptx
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension
 
Artificial intelligence in Dermatology.pptx
Artificial intelligence in Dermatology.pptxArtificial intelligence in Dermatology.pptx
Artificial intelligence in Dermatology.pptx
 
tayloranderson44444444444444444444444444444444.pptx
tayloranderson44444444444444444444444444444444.pptxtayloranderson44444444444444444444444444444444.pptx
tayloranderson44444444444444444444444444444444.pptx
 
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision MedicineAdoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
Adoptive Design: Optimizing Clinical Trial Strategies for Precision Medicine
 
Strategies and Options For Making India Zero Waste Water-26-2-24.pptx
Strategies and Options For Making India Zero Waste Water-26-2-24.pptxStrategies and Options For Making India Zero Waste Water-26-2-24.pptx
Strategies and Options For Making India Zero Waste Water-26-2-24.pptx
 

applied strategic biosimilars success

  • 1. applied strategic 10 years experience in biosimilars: launch to the future. What matters most? Presentation by Dr Richard Littlewood 9 March 2016 8th Biosimilars Congregation applied strategic 1
  • 2. Analytics What we all know? Definition of similarity concept for biologic medicines defined a new market for biosimilars applied strategic 2 Preclinical PK/PD Clinical Trials Process development Source: McCamish 2011, CMHP/437/04 Biological Characterization Physiochemical Characterization “A company may choose to develop a new biological medicinal product claimed to be “similar” to a reference medicinal product” CHMP/437/04
  • 3. What do we expect? Rapid growth to $35B global market for biosimilars, predicted by observers applied strategic 3 Biosimilars global sales [2013-2020, $B] 60% CAGR Biosimilars Biologics 175 285 2013 2020 Source: Merck Serono 2014, Blackstone & Joseph 2013, EGA 2015, Evaluate Group 2014
  • 4. When did it start? Radical regulatory affairs innovation by EMEA, 2004 and key guidance launched biosimilars applied strategic Source: applied strategic analysis EMA Legal progress Regulatory progress 2001 2002 2003 2004 2005 2006 Directive 2003/63/EC “Annex I” biosimiars recognition Directive 2004/27/EC published Directive 2004/27/EC in law First biosimilar approved Product guidelines hGh, insulin, EPO, G-CSF Comparability guidelines Quality, non- clinical, clinical guidelines
  • 5. Where did it start? In Europe work started pre-2000; alternative biologics versions were marketed in LATAM also applied strategic 5 Europe 1998: Start development of Binocrit® (epoetin alfa) Mexico 1999: launch of Bioyetin (epoetin alfa) Source: applied strategic analysis
  • 6. What is the impact? Early product launches in Europe highlight commercial and patient access success applied strategic 6 • Launch of biosimilar Epoetin alfa in Europe • 5 year healthcare cumulative savings to Germany, €0.6B • Typically 35% cost reduction • 255,000 patient-years exposure Biosimilar Epoetin Alfa Launch 2007 Commercial & patient access success Source: applied strategic analysis
  • 7. What is the impact? A relatively small set of biosimilar products are currently marketed applied strategic 7 Omnitrope Silapo EpoHexal Binocrit Abseamed Tevalgrastim Ratiograstim Biograstim Retracrit Nivestim Remsima Ovaleap Inflectra Grastofil Bemfola Accofil Abasglar Benepali Zarzio FilgrastimHexal 20162006 2011 Source: GaBI, Biosimilars approved in Europe 2016 European product approvals
  • 8. What is the impact? Few companies own a majority of the assets: market looks an oligopoly… applied strategic 8 Omnitrope Silapo EpoHexal Binocrit Abseamed Tevagrastim Ratiograstim Biograstim Retracrit Nivestim Remsima Ovaleap Inflectra Grastofil Bemfola Accofil Abasglar Benepali Zarzio FilgrastimHexal 20162006 2011 Source: GaBI, Biosimilars approved in Europe 2016 European product approvals Assets owned by companies with portfolio of biosimiars
  • 9. What is the future? Patent expiry, freedom to operate for many biologics defines a $B expansion of opportunity Monoclonal antibodies approved/ under review in EU/ US [Patent expiry] applied strategic 9 Oncology Non- oncology 17 32 <2020 >2020 Source: applied strategic analysis • 49 monoclonal antibody products have potential for biosimilar launch • Launch of biosimilar versions of these products represents a step change in opportunity size Potential value $20-30B Expiry of patent, year
  • 10. What is the future? New biosimilar products – based on antibodies – imply increasing manufacturing complexity applied strategic 10 Trade Name (INN) Originator Approval date Tysabri® (Natalizumab) Biogen Idec 2004 Lucentis® (Ranibizumab) Roche/ Novartis 2006 Cimzia® (Certolizumab) UCB 2009 Stelara® (Ustekinumab) Johnson & Johnson 2009 Eylea® (Aflibercept) Bayer/ Regeneron 2011 Zaltrap® (Aflibercept) Sanofi/ Regeneron 2012 Prolia®/Xgeva® (Denosumab) Amgen 2011 Benlysta® (Belimumab) GlaxoSmithKline 2011 Soliris® (Eculizumab) Alexion 2007, 2011 Source: applied strategic analysis • Future products with potential to be biosimilars are based on antibodies • Greater manufacturing complexity, defining a special capability need
  • 11. What is the future? Success with biosimilars is driving increasing simplicity in evidence needed for approval applied strategic 11 “a confirmatory clinical trial may not be necessary” EMA 2014 “waiving clinical trials may be accomplishable for biosimilar rhG-CSF” EMA 2015 “pre-licensing safety study, immunogenicity assessment waived? EMA 2015 “PK PD results may make a comparative efficacy study unnecessary” FDA 2015 Source: applied strategic analysis
  • 12. What is the future? A broad range of competitors now are present: partners are a major part of the business applied strategic 12 Merck Sorono, Merck Pfizer, Daiichi-Sankyo Boehringer Ingelheim, biogen idec Baxter, Lilly, Amgen Sandoz, Teva Hospira, Mylan STADA, Dr. Reddy’s, actavis. Cipla, Gideon Richter Fujifilm Samsung GE Healthcare Celltrion Innovative companies Generics manufacturers Others Biocon Lonza Formycon Patheon Intas IBA Bioton Zydus Broughton Zydus Wockhardt CMC Rentschler Key partners: supporting development, contract development, manufacturers Competitors: Commercializing biosimilar products Source: applied strategic analysis
  • 13. What drives success? First commercial phase. Success factors: protein characterization, regulatory affairs applied strategic 13 Development Clinical Regulatory Launch Commercial Cell line to product development; protein characterization; comparability Agency relationships, strategic leadership; pathway interpretation Tender management, pricing strategy. Customer awareness Customer awareness, defending against restrictions; Policy management Success Factors for Biosimilar Competition: First Commercial Phase (2006-2016)
  • 14. What drives success? Next 10 years Success factors: commercial power, speed to market applied strategic 14 Development Clinical Regulatory Launch Commercial Complex protein manufacture R&D partnerships Capability to delivery clinical studies rapidly Marketing & Sales power Race to market Success Factors for Biosimilar Competition: Second Commercial Phase (2017-2027)
  • 15. Speaker profile Dr. Richard Littlewood • Richard is the founder of the strategy firm applied strategic • is a physician with clinical practice experience and a management consultant who has worked for 15 years addressing strategic and operational issues in health, pharma • He is a UK GMC registered physician, has an MA from Trinity College, Cambridge and is a graduate of the Sloan Masters management program at London Business School. • Richard pioneered on biosimilars strategy and has extensive experience in many developed and emerging markets. 15 [appliedstrategic founder] Dr. Richard Littlewood • Adviser to global pharmaceutical companies involved in biosimilar development in Europe, USA and emerging markets since 2006 [Conflicts]